Moreover, TFRC, as a molecular protein on the cell surface that includes cell adhesion molecule binding, may be used in the future for CAR-T therapy related to pancreatic cancer immunotherapy (by targeting TFRC to induce the patient’s own immune cells to attack the tumor). Here, TFRC is linked to familial pancreatic carcinoma.